Genetic Technologies Ltd.
GENE
GENE was delisted on the 16th of October, 2024.
10 hedge funds and large institutions have $69.1K invested in Genetic Technologies Ltd. in 2024 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
43% more funds holding
Funds holding: 7 → 10 (+3)
82% less capital invested
Capital invested by funds: $377K → $69.1K (-$308K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$12.9K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$7.88K |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$2.22K |
| 4 |
Morgan Stanley
New York
|
+$1.25K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$606 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$210K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$44.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $20.7K | -$44.2K | -49,686 | -64% |
|
|
2
Morgan Stanley
New York
| $15K | +$1.25K | +1,400 | +8% |
|
|
3
BNP Paribas Financial Markets
Paris,
France
| $11.7K | +$2.22K | +2,500 | +20% |
|
|
TSS
4
Two Sigma Securities
New York
| $11.2K | +$12.9K | +14,457 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $6.87K | +$7.88K | +8,866 | New |
|
6
RhumbLine Advisers
Boston,
Massachusetts
| $2.79K | – | – | – |
|
|
7
Citadel Advisors
Miami,
Florida
| $510 | +$606 | +682 | New |
|
|
FDCDDQ
8
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $310 | – | – | – |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $13 | +$16 | +18 | New |
|
|
ATS
10
Ashton Thomas Securities
Rochester,
New York
| $4 | +$4 | +5 | New |
|
|
AC
11
Armistice Capital
New York
| – | -$210K | -140,000 | Closed |
|
GENE Hedge Fund Activity: Q3 2024 in Review
10 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Genetic Technologies Ltd. (GENE) for Q3 2024, worth a combined $69.1K — down 82% from $377K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new GENE positions and 2 closed out — a net gain of 3 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $12.9K. The largest seller was Armistice Capital, exiting entirely with an estimated $210K sold.
- 10 institutional investors held Genetic Technologies Ltd. (GENE) as of Q3 2024, up from 7 in Q2 2024.
- Funds reported $69.1K of Genetic Technologies Ltd. stock for Q3 2024, down 82% quarter-over-quarter.
- 5 funds opened new Genetic Technologies Ltd. positions in Q3 2024 and 2 closed out, a net change of +3 holders.
- The largest Genetic Technologies Ltd. buyer in Q3 2024 was Two Sigma Securities, an estimated $12.9K added.
- The largest Genetic Technologies Ltd. seller in Q3 2024 was Armistice Capital, an estimated $210K sold.
Based on aggregated 13F filings for Q3 2024.